Back

FOG2 coding variant Ser657Gly is associated with Coronary Microvascular Disease through altered hypoxia-mediated gene transcription

Guerraty, M.; Verma, S.; Ko, Y.-A.; McQuillan, M.; Conlon, D.; Tobias, J. W.; Levin, M. G.; Haury, W.; Zhang, C.; Judy, R.; Regeneron Genomics Center, ; PennMedicine Biobank, ; Tishkoff, S.; Damrauer, S. M.; Arany, Z.; Rader, D. J.

2023-05-28 genetic and genomic medicine
10.1101/2023.05.22.23290352 medRxiv
Show abstract

RationaleThe coronary microvasculature is crucial for proper cardiac function, and coronary microvascular disease (CMVD) has emerged as an underdiagnosed and undertreated cause of ischemic heart disease. Friend of GATA 2 (FOG2) is a transcriptional co-regulator crucial for coronary development and the maintenance of the coronary microvasculature in adult mice.Little is known about the role of FOG2 in humans or its role in CMVD. ObjectiveHere, we report a genotype-first approach to determine the role of FOG2 in human coronary microvascular disease. FindingsWe performed Phenome-Wide association studies and deep cardiac phenotyping through the Electronic Health record in patients with FOG2 coding variants and identified an association between rs28374544 (A1969G, S657G) and CMVD. Patients with S657G had increased chest pain, smaller burden of obstructive coronary artery disease, and altered coronary blood flow. Differential gene and pathway analysis using several genomic datasets showed that carriers of S657G have increased expression of genes involved in angiogenesis, glycolysis, and the hypoxia-inducible factor (HIF) pathway. In vitro functional studies show that FOG2 S657G promotes angiogenic gene expression and angiogenesis while decreasing oxygen consumption rate. FOG2 also regulates HIF1a occupancy of angiogenic genes. ConclusionsWe identified a human missense variant which is associated with CMVD and established a potential mechanism by which the variant may altered angiogenic gene expression.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Circulation: Genomic and Precision Medicine
42 papers in training set
Top 0.1%
41.5%
2
Genetics in Medicine
69 papers in training set
Top 0.3%
7.2%
3
Cardiovascular Research
33 papers in training set
Top 0.1%
5.1%
50% of probability mass above
4
Circulation
66 papers in training set
Top 0.8%
4.2%
5
Journal of the American Heart Association
119 papers in training set
Top 2%
3.8%
6
Arteriosclerosis, Thrombosis, and Vascular Biology
65 papers in training set
Top 0.8%
2.5%
7
Journal of the American College of Cardiology
12 papers in training set
Top 0.2%
2.5%
8
Journal of Internal Medicine
12 papers in training set
Top 0.1%
1.9%
9
Atherosclerosis
29 papers in training set
Top 0.7%
1.8%
10
European Journal of Preventive Cardiology
13 papers in training set
Top 0.4%
1.8%
11
Human Genomics
21 papers in training set
Top 0.2%
1.4%
12
PLOS ONE
4510 papers in training set
Top 57%
1.4%
13
Journal of Clinical Medicine
91 papers in training set
Top 4%
1.3%
14
Scientific Reports
3102 papers in training set
Top 65%
1.3%
15
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.5%
1.2%
16
BMC Medical Genomics
36 papers in training set
Top 1.0%
0.9%
17
Circulation Research
39 papers in training set
Top 1.0%
0.8%
18
BMC Cardiovascular Disorders
14 papers in training set
Top 1%
0.8%
19
Critical Care
14 papers in training set
Top 0.6%
0.8%
20
PLOS Medicine
98 papers in training set
Top 4%
0.8%
21
Journal of Infection
71 papers in training set
Top 3%
0.7%
22
European Journal of Human Genetics
49 papers in training set
Top 1%
0.7%
23
The American Journal of Cardiology
15 papers in training set
Top 1%
0.7%
24
British Journal of Anaesthesia
14 papers in training set
Top 0.9%
0.7%
25
Stroke
35 papers in training set
Top 0.9%
0.7%
26
Human Genetics
25 papers in training set
Top 0.5%
0.5%
27
European Heart Journal
16 papers in training set
Top 1.0%
0.5%
28
Journal of Translational Medicine
46 papers in training set
Top 4%
0.5%
29
Journal of Clinical Investigation
164 papers in training set
Top 8%
0.5%